High serum prolactin associated with poor prognosis in carcinoma of the prostate

Print
Published on Thursday, 23 November 2017

Abstract

Seventy patients with carcinoma of the prostate have had regular estimations of serum prolactin levels during a 10-month period, and were followed up for a further 6 months.

Of 21 patients who recorded at least one high serum prolactin, 10 (48%) died during these 16 months, while of 50 with normal prolactin, only 2 (4%) died. Ten (21%) of the 47 patients on oestrogen or anti-androgen therapy died, and 9 of these had a high prolactin. This contrasts with 2 (14%) deaths of 14 who had had either bilateral orchiectomy or radiotherapy to the prostate. One of the 2 who died had a high prolactin

It is concluded that an elevated serum prolactin in treated carcinoma of the prostate is associated with progression of the disease and a poor prognosis.

 

 

About this publication.

 

See also:

- The Di Bella Method (A Fixed Part);

- The Di Bella Method (DBM) in the treatment of prostate cancer: a preliminary retrospective study of 16 patients and a review of the literature;

- Evaluation of the safety and efficacy of the first-line treatment with somatostatin combined with melatonin, retinoids, vitamin D3, and low doses of cyclophosphamide in 20 cases of breast cancer: a preliminary report;

- The Di Bella Method (DBM) improved survival, objective response and performance status in a retrospective observational clinical study on 122 cases of breast cancer;

- Complete objective response to biological therapy of plurifocal breast carcinoma.